ScholarLens Back to search
2005•Clinical Infectious DiseasesRequires access

Nebulized Colistin in the Treatment of Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Andrea Lay‐Hoon Kwa, Ching‐Hui Loh, Jenny G. Low, Asok Kurup, Vincent H. Tam

Open publisher page 192 citations

Abstract

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.

About this research paper

What this paper is about

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.

Why it matters

OpenAlex reports 192 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.

Key concepts: Colistin, Acinetobacter baumannii, Polymyxin, Pseudomonas aeruginosa, Medicine, Pneumonia, Acinetobacter, Polymyxin B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Nebulized Colistin in the Treatment of Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa — Research Paper | ScholarLens